


| | | |
|---|---------------------------------|------------------------------|
| Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. 20 FWC | SERIAL NO. 08/867,612 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | APPLICANT Wang et al. | |
| | FILING DATE June 2, 1997 | GROUP Art Unit: 1644 |



U.S. PATENT DOCUMENT

| EXAMINER INITIALS | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|----------------------|--------------------|------|------|-------|----------|-------------------------------|
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|--|--|--------------------|--|--|--|--|--|--|------|---------|-------|----------|-------------|----|
| | | | | | | | | | | | | | YES | NO |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


| | | |
|-----------|--|--|
| <i>me</i> | | Banapour et al., "The AIDS-associated retrovirus is not sensitive to lysis or inactivation by human serum" Virology 152:268-271, (1986). |
| | | Barbacid et al., "Humans have antibodies capable of recognizing oncoviral glycoproteins: Demonstration that these antibodies are formed in response to cellular modification of glycoproteins rather than as consequence of exposure virus: Proc. Natl. Acad. Sci. USA 77:1617-1621 (1980) |
| <i>n</i> | | Bartholomew et al., "Lysis of oncornaviruses by human serum" J Exp Med, 147:844-853, (1978) |
| | | Bartholomew et al., "Mechanism of antibody-independent activation of the first component of complement (C1) on retrovirus membranes" Biochem 19:2847-2853 (1980) |
| <i>n</i> | | Brenner, M. "Genetic marketing and manipulation of hematopoietic progenitor cells using retroviral vectors." Immunmethods 5:204-210: (1994) |
| <i>n</i> | | Cooper et al., "Lysis of RNA tumor viruses by human serum: Direct antibody-independent triggering of the classical complement pathway" J Exp Med, 144:970-984, (1976). |

EXAMINER

Banner 3/25/01

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|---------------------------------|------------------------------|
| Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. 20 FWC | SERIAL NO. 08/867,612 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | APPLICANT Want et al. | |
|  | FILING DATE June 2, 1997 | GROUP Art Unit: 1644 |

U.S. PATENT DOCUMENT

| EXAMINER INITIALS | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|----------------------|--------------------|------|------|-------|----------|-------------------------------|
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|--|--------------------|------|---------|-------|----------|-------------|----|
| | | | | | | YES | NO |
| | | | | | | | |
| | | | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


| | | |
|-----------|--|--|
| <i>AL</i> | | Galili et al., "Evolution and pathophysiology of the human natural anti-a-galactosyl IgG (Anti-Gal) antibody" Springer Semin Immunopathol, 15:155-171, (1993) |
| | | Geyer et al., "Major oligosaccharides in the glycoprotein of friend murine leukemia virus: structure elucidation by one- and two- dimensional proton nuclear magnetic resonance and methylation analysis" Biochemistry 23:5628-5637 (1984) |
| <i>AL</i> | | Hamadeh et al., "Human natural anti-gal IgG regulates alternative complement pathway activation on bacterial surfaces" J Clin Invest, 89:1223-1235, (1992) |
| | | Hoshino et al., " Human T-cell leukaemia virus is not lysed by human serum" Nature, 310:324-325, (1984) |
| <i>MB</i> | | Isaacs et al., "Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence" Proc Natl Acad Sci, USA, 89:628-632, (1992) |
| | | Joziasse et al., "Bovine a1-3 galactosyltransferase: Isolation and characterization of a cDNA clone" J Biol Chem, 264:14290-14297, (1989) |
| <i>AL</i> | | Kohn et al., "Retroviral-mediated gene transfer into mammalian cells" Blood Cells 13:285-298, (1987) |
| | | Larsen et al., "Molecular cloning, sequence, and expression of a human GDP-L-fucose: B-D-galactoside 2-a-L-fucosyltransferase cDNA that can form the H blood group antigen" Proc Natl Acad Sci, USA 87:6674-6678, (1990) |

EXAMINER

DATE CONSIDERED

Gsmal 3/28/01

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|--------------------------------|------------------------------|
| Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. 20 FWC | SERIAL NO. 08/867,612 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | |
|  | APPLICANT | |
| | Wang et al. | |
| | FILING DATE | GROUP Art Unit: |
| | June 2, 1997 | 1644 |

U.S. PATENT DOCUMENT

| EXAMINER INITIALS | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|----------------------|--------------------|------|------|-------|----------|-------------------------------|
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |


FOREIGN PATENT DOCUMENTS

| | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|--|--------------------|------|---------|-------|----------|-------------|----|
| | | | | | | YES | NO |
| | | | | | | | |
| | | | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|----------|-----------------|---|
| <i>M</i> | | Lowe, "Molecular cloning, expression, and uses of mammalian glycosyltransferases" Semin cell Biol, 2:289-307, (1991) |
| | | Lower et al., "Heterophil human antibodies recognize oncovirus envelope antigens: Epidemiological parameters and immunological specificity of the reaction" Virology, 109:409-417, (1981) |
| <i>M</i> | | Martinez et al., " Partial reconstitution of replication-competent retrovirus in helper cells with partial overlaps between vector and helper cell genomes" Human Gene Therapy 7:705-712, (1996) |
| | | Mulligan, R. "The basic science of gene therapy", Science 260:926-931 (1993) |
| <i>M</i> | | McNearney et al., "Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement-mediated neutralization of viral infectivity" J Exp Med 166:1525-1535, (1987) |
| <i>M</i> | | Neething et al., "Protection of pig kidney (PK15) cells from the cytotoxic effect of anti-pig antibodies by a-galactosyl oligosaccharides" Transplantation, 57:959-963, (1994) |
| | | Ram et al., "Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors" J Neurosurg, 79:400-407, (1993) |
| <i>P</i> | | Repik et al., "Differential host-dependent expression of a-galactosyl epitopes on viral glycoproteins: a study of eastern equine encephalitis virus as a model" J Gen Virol 75:1177-1181, (1994) |
| EXAMINER | DATE CONSIDERED | |
| | GAMMER 3/18/01 | |

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|---------------------------------|------------------------------|
| Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. 20 FWC | SERIAL NO. 08/867,612 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | |
|  | APPLICANT | |
| | Wang et al. | GROUP Art Unit: 1644 |
| | FILING DATE June 2, 1997 | |

U.S. PATENT DOCUMENT

| EXAMINER INITIALS | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|----------------------|--------------------|------|------|-------|----------|-------------------------------|
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|--|--------------------|------|---------|-------|----------|-------------|----|
| | | | | | | YES | NO |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|-----------|--|---|
| <i>M</i> | | Rother et al., "Inhibition of complement-mediated cytolysis by the terminal complement inhibitor of herpesvirus saimiri" J Virol, 68:730-737, (1994) |
| | | Rother et al., "Protection of retroviral vector particles in human blood through complement inhibition" Human Gene Therapy 6:429-435, (1995) |
| <i>Ar</i> | | Rother et al., "A novel mechanism of retrovirus inactivation in human serum mediated by anti-a-galactosyl Natural antibody" J Exp Med 182:1345-1355, (1995) |
| | | Sandrin et al., "Biochemical features of pig to human xenografts " J leukocyte biol, 0 (suppl):66, (1993) |
| <i>Ar</i> | | Sandrin et al, "Anti-pig IgM antibodies in human serum react predominantly with gal (a1-3) gal epitopes" Proc Ntl Acad Sci, USA 90:11392-11395 |
| | | Sandrin et al., "Anti-pig IgM antibodies in human serum react predominantly with gal (a1-3) gal epitopes" Proc Natl Acad Sci, USA, 90:11391-11395, (1993) |
| <i>N</i> | | Sandrin et al., "Gal a(1-3) gal, the major xenoantigen (s) recognised in pigs by human natural antibodies" Immunol review, 141:160-190, (1994) |
| | | Sherwin et al, "Complement-mediated lysis of type-C virus: Effect of primate and human sera on various retroviruses: Int J Cancer, 21:6-11, (1978) |
| <i>m</i> | | Snyder et al., "Specificity of human antibodies to oncovirus glycoproteins: Recognition of antigen by natural antibodies directed against carbohydrate structures: Proc Natl Acad Sci, USA 77:1622-1626, (1980) |
| | | |


EXAMINER

DATE CONSIDERED

Gamber 3/25/01

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|---------------------------------|------------------------------|
| Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. 20 FWC | SERIAL NO. 08/867,612 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | APPLICANT Wang et al. | |
| | FILING DATE June 2, 1997 | GROUP Art Unit: 1644 |



U.S. PATENT DOCUMENT

| EXAMINER INITIALS | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|----------------------|--------------------|------|------|-------|----------|-------------------------------|
| | | | | | | |
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|--|--------------------|------|---------|-------|----------|-------------|----|
| | | | | | | YES | NO |
| | | | | | | | |
| | | | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


| | | |
|---|--|--|
| m | | Spear et al., "Direct binding of complement component Clq to human immunodeficiency virus (HIV) and human T lymphotropic virus-I (HTLV- I) coinfecting cells" AIDS Research human retrovirus, 7:579-585. (1991) |
| | | Takuechi et al., "Type c retrovirus inactivation by human complement is determined by both the viral genome and the producer cell" J Virol, 68:8001-8007, (1994) |
| n | | Thall et al., "Distrubution of Galal-3galB1-4GlcNAc residues on secreted mammalian glycoproteins (Thyroglobulin, fibrinogen, and Immunoglobulin G) as measured by a sensitive solid-phase radioimmunoassay" Biochemistry, 29:3959-3965, (1990) |
| | | Thiry et al., "Factors which influence inactivation of vesicular stomatitis virus by fresh human serum" Virology, 87:384-393, (1978) |
| n | | Vaughn et al., "Biochemical analysis of pig xenoantigens detected by human antibodies" Transplantation Proc. 25:2919-2920, (1993) |
| | | Welsh et al., "Human serum lyses RNA tumor viruses" Natural, 257:612-614, (1975)). |
| n | | Welsh et al., "Inactivation and lysis of oncornaviruses by human serum" Virology 74:432-440, (1976). |
| | | Widner et al., "Immunological aspects of grafting in the mammalian central nervous system. A review and speculative synthesis" Brain Res Rev, 13:287-324, (1988) |
| | | |
| | | |

EXAMINER

DATE CONSIDERED

Gumbel 3/18/01

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|--|--------------------------------|---------------------------------|
| Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. 20 FWC | SERIAL NO. 08/867,612 |
|  | APPLICANT Wang et al. | FILING DATE June 2, 1997 |
| | | GROUP Art Unit: 1644 |

U.S. PATENT DOCUMENT

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

[illegible]

| | |
|-----------------------------------|-----------------|
| EXAMINER <i>Gsmora 3/28/07</i> | DATE CONSIDERED |
|-----------------------------------|-----------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.